Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Claritas Pharmaceuticals Inc (KALTF)

Claritas Pharmaceuticals Inc (KALTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing Globe Newswire - Tue Feb 22, 2022

SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022 Globe Newswire - Wed Feb 9, 2022

Ethics Committee Approval is Final Step Prior to Enrollment of Claritas’ Phase 1 Clinical Study of R-107...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners Globe Newswire - Wed Jan 26, 2022

SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns Globe Newswire - Mon Jan 17, 2022

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or...

CLAS.VN : 0.025 (-16.67%)
OTC.VN : 0.325 (+3.17%)
KLY.VN : 0.045 (unch)
KALTF : 0.1100 (unch)
Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners Globe Newswire - Mon Jan 17, 2022

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd. Globe Newswire - Wed Jan 12, 2022

SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns Globe Newswire - Wed Dec 22, 2021

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease Globe Newswire - Tue Dec 21, 2021

Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the Disease...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis Globe Newswire - Mon Dec 20, 2021

Claritas to Initiate Phase 2 Clinical Testing of R-107 in Treatment of COVID-Related Sepsis Following Completion of Phase 1 Study...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Provides Update Regarding Phase 1 Clinical Study Globe Newswire - Thu Nov 18, 2021

SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)

Barchart Exclusives

Earnings, the Yen and Other Key Things to Watch This Week Barchart - Sun May 5, 2:00PM CDT
This week is relatively quiet on the news front, but there are still earnings due out and plenty of other macro factors to watch. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot